A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2015
At a glance
- Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
- Indications Mesothelioma; Prostate cancer
- Focus Adverse reactions
- Sponsors Momotaro-Gene
- 10 Jun 2017 Biomarkers information updated
- 21 Aug 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 22 Jun 2011 Planned end date changed from Nov 2011 to Nov 2012 as reported by ClinicalTrials.gov record.